Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Deuterated drugs and biomarkers in the COVID-19 pandemic
ID
Jansen-van Vuuren, Ross D.
(
Author
),
ID
Jedlovčnik, Luka
(
Author
),
ID
Košmrlj, Janez
(
Author
),
ID
Massey, Thomas E.
(
Author
),
ID
Derdau, Volker
(
Author
)
PDF - Presentation file,
Download
(3,59 MB)
MD5: F23C1C6747856A5B6139D594A055AB73
URL - Source URL, Visit
https://pubs.acs.org/doi/10.1021/acsomega.2c04160
Image galllery
Abstract
Coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Initially identified in Wuhan (China) in December 2019, COVID-19 rapidly spread globally, resulting in the COVID-19 pandemic. Carriers of the SARS-CoV-2 can experience symptoms ranging from mild to severe (or no symptoms whatsoever). Although vaccination provides extra immunity toward SARS-CoV-2, there has been an urgent need to develop treatments for COVID-19 to alleviate symptoms for carriers of the disease. In seeking a potential treatment, deuterated compounds have played a critical role either as therapeutic agents or as internal MS standards for studying the pharmacological properties of new drugs by quantifying the parent compounds and metabolites. We have identified >70 examples of deuterium-labeled compounds associated with treatment of COVID-19. Of these, we found 9 repurposed drugs and >20 novel drugs studied for potential therapeutic roles along with a total of 38 compounds (drugs, biomarkers, and lipids) explored as internal mass spectrometry standards. This review details the synthetic pathways and modes of action of these compounds (if known), and a brief analysis of each study.
Language:
English
Keywords:
COVID-19
,
hydrogen isotopes
,
inhibitors
,
metabolism
,
pharmaceuticals
Work type:
Article
Typology:
1.02 - Review Article
Organization:
FKKT - Faculty of Chemistry and Chemical Technology
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
Str. 41840-41858
Numbering:
Vol. 7, iss. 46
PID:
20.500.12556/RUL-144314
UDC:
547.8:546.11
ISSN on article:
2470-1343
DOI:
10.1021/acsomega.2c04160
COBISS.SI-ID:
131181827
Publication date in RUL:
14.02.2023
Views:
588
Downloads:
446
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
ACS omega
Shortened title:
ACS omega
Publisher:
American Chemical Society
ISSN:
2470-1343
COBISS.SI-ID:
525873945
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
COVID-19
,
izotopi vodika
,
inhibitorji
,
presnova
,
zdravila
Projects
Funder:
Other - Other funder or multiple funders
Funding programme:
Queen’s University, Rapid Response Funding
Funder:
Other - Other funder or multiple funders
Funding programme:
Southeastern Ontario Academic Medical Organization
Funder:
EC - European Commission
Funding programme:
H2020
Project number:
945380
Name:
EUTOPIA-Science and Innovation Fellowships
Acronym:
EUTOPIA-SIF
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0230
Name:
Organska kemija: sinteza, struktura in aplikacija
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back